PPARδ Activation and Tumorigenesis in Mice
Author Information
Author(s): Claire B. Pollock, Yuzhi Yin, Hongyan Yuan, Xiao Zeng, Sruthi King, Xin Li, Levy Kopelovich, Chris Albanese, Robert I. Glazer
Primary Institution: Georgetown University Medical Center
Hypothesis
The study investigates the role of PDK1 in mammary tumorigenesis and its interaction with PPARδ activation.
Conclusion
The study found that PPARδ activation accelerates mammary tumorigenesis, particularly in mice expressing PDK1.
Supporting Evidence
- Transgenic mice expressing PDK1 showed increased tumor formation when treated with GW501516.
- The study identified a distinct metabolic gene expression profile associated with PPARδ activation.
- GW501516 treatment reduced tumor-free survival in PDK1 mice compared to wild-type mice.
Takeaway
This study shows that a specific protein can make mice more likely to develop breast cancer when given a certain treatment.
Methodology
Transgenic mice expressing PDK1 were treated with a PPARδ agonist and assessed for tumor formation and gene expression.
Potential Biases
Potential bias in the interpretation of results due to the specific genetic background of the mice used.
Limitations
The study primarily focuses on mouse models, which may not fully replicate human cancer biology.
Participant Demographics
Transgenic mice and wild-type littermates were used in the study.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website